- Oral presentation
- Open Access
Post-radioiodine management of patients with Graves' disease
BMC Proceedings volume 6, Article number: O37 (2012)
Radioiodine is a safe and effective treatment for Graves' disease. Iatrogenic hypothyroidism is very common after treatment, but its onset is unpredictable. Even a short episode of hypothyroidism can result in significant morbidity and ideally should be avoided. In Newcastle a standard dose of radioiodine (400MBq) is used, but for historical reasons two different protocols are used after radioiodine: Regimen A: regular clinical and biochemical monitoring and initiation of levothyroxine when serum thyroid hormones have normalized, and Regimen B: block and replace with Carbimazole and levothyroxine starting 2 weeks post-radioiodine and continuing for 6 months, then withdrawing Carbimazole, but continuing with levothyroxine long-term.
The objective was to compare the two protocols for incidence of biochemical and clinical hypothyroidism during a 12 month post-radioiodine follow-up period and effects on weight gain and development or progression of orbitopathy. Patients with Graves' disease who were treated between January 2008-December 2009 were included. The medical records were reviewed and data were collected and analyzed.
One hundred and twenty two patients were studied, 78 treated with Regimen A and 43 with Regimen B. Euthyroidism at 8 weeks, 6 months and 12 months post-radioiodine was achieved in 50%, 64% and 73% of patients with Regimen A and 65.1%, 71% and 65% in patients with regimen B respectively. Clinical hypothyroidism during follow-up was commoner in Regimen A than B (52.6% vs 16.3% respectively, p<0.05). Weight gain was reported more frequently in Regimen A than B (43.6% vs 20.9%, p<0.05). The incidence of new Graves' orbitopathy developing after radioiodine was higher in Regimen A than B (11.1% vs 5.3%).
A 6 month course of block and replace followed by levothyroxine after a standard 400MBq dose of radioiodine is associated with better clinical outcomes than a watchful approach and initiation of levothyroxine based on biochemical and clinical indicators.
About this article
Cite this article
Collins, K., Perros, P. & Horsefield, J. Post-radioiodine management of patients with Graves' disease. BMC Proc 6, O37 (2012). https://doi.org/10.1186/1753-6561-6-S4-O37
- Weight Gain
- Medical Record
- Effective Treatment
- Thyroid Hormone